Physician profile
John D Simpson
NPI 1871512558
$1,475.11
in general payments reported to CMS, 2019-2025
22 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $126 · 2021: $253 · 2022: $288 · 2023: $232 · 2024: $148 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $218.18 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $199.48 | 2019-2022 | |
| Neos Therapeutics, Lp | $145.31 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Tris Pharma INC | $140.40 | 2019-2022 | |
| Pfizer INC. | $112.92 | 2019-2025 | |
| Glaxosmithkline, LLC. | $97.76 | 2020-2025 | Bexsero, Pediarix, Rotarix |
| Corium, LLC | $84.69 | 2021-2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $84.32 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $79.72 | 2019-2023 | Proquad, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $40.43 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $39.92 | 2022-2023 | Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $35.88 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $35.48 | 2021-2022 | |
| Adlon Therapeutics L.P. | $28.45 | 2020-2021 | |
| Abbott Laboratories | $21.65 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $20.35 | 2025 | Nuplazid |
| Alk-Abello, INC | $17.92 | 2023 | Grastek, Odactra, Ragwitek |
| Vertical Pharmaceuticals, LLC | $17.36 | 2019 | |
| Sobi, INC | $15.67 | 2019 | |
| Genentech USA, INC. | $13.97 | 2021 | |
| Kaleo, INC. | $13.90 | 2022 | |
| Shire North American Group INC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.